• Sensitivity, specificity, positive and negative likelihood ratio, positive and negative predicted value of recording "definite" AF episodes (≥30 seconds) with the Cardioskin™ versus 3-lead Holter recorder after a 24 hour recording period[performance]. [ Time Frame: 24 hours ]
  Sensitivity, specificity, positive and negative likelihood ratio, and positive and negative predicted value of recording "definite" AF episodes (≥30 seconds) with the Cardioskin™ versus the 3-lead Holter recorder after a 24 hour recording period (adjudicated events)
• The incidence of device related (serious) adverse events [safety]. [ Time Frame: 14 days ]
  The incidence of device related (serious) adverse events during the course of the clinical investigation.

• Determining the accuracy of "definitive" AF detection (≥30 seconds) of the Cardioskin™ as compared to a 3-lead Holter recorder in patients with known paroxysmal AF. [ Time Frame: 24 hours ]
  Sensitivity, specificity, positive and negative likelihood ratio, and positive and negative predicted value of recording "definite" AF episodes (≥30 seconds) with the Cardioskin™ versus the 3-lead Holter recorder after a 24 hour recording period (adjudicated events)
• The safety of Cardioskin™. [ Time Frame: 14 days ]
  The incidence of device related (serious) adverse events during the course of the clinical investigation.

• Time until first "definite" AF (≥ 30 seconds) episode detection of the Cardioskin™. [ Time Frame: 14 days ]
  Time until first "definite" AF episode detected by the Cardioskin™.
• Incidence and length of AF episodes after 13 day recording period with Cardioskin™ (based on standard ECG analysis) [ Time Frame: 13 days ]
  The incidence and length of AF episodes after a 13 day recording period, based on a standard ECG analysis, after first "definite" AF episode detected during this period.
• Qualitative comparison of the relevant cardiac parameters as recorded by the Cardioskin™ to these recorded by a 3-lead holter, as assessed per standard ECG analysis after 24 hours. [ Time Frame: 24 hours ]
  A qualitative comparison of the relevant cardiac parameters as recorded by the Cardioskin™ to these recorded by a 3-lead Holter recorder, assessed per standard ECG analysis.
• The timing and frequency of subject reported AF episodes and timing, frequency and duration of AF episodes as detected by Cardioskin™ after 14 day recording period. [ Time Frame: 14 days ]
  The timing and frequency of AF symptoms as recorded by the subject and the timing, frequency and duration of AF episodes as detected by the Cardioskin™ after a 14 day recording period.
• Frequency and duration (total duration & longest) of arrhythmia symptoms as recorded by the subject and the nature, timing, frequency and duration (longest) of arrhythmia as detected by Cardioskin™ after a 14 day period(based on standard ECG analysis). [ Time Frame: 14 days ]
  The timing and frequency of arrhythmia symptoms as recorded by the subject and the nature, timing, frequency and duration of arrhythmias as detected by the Cardioskin™ after a 14 day recording period, based on a standard ECG analysis.

• To examine the time until first AF episode detection of the Cardioskin™. [ Time Frame: 14 days ]
  Time until first "definite" AF episode detected by the Cardioskin™.
• To determine the ability of Cardioskin™ to detect AF in patients with known paroxysmal AF. [ Time Frame: 13 days ]
  The incidence and length of AF episodes after a 13 day recording period, based on a standard ECG analysis, after first "definite" AF episode detected during this period.
• To investigate the quality of the signals of Cardioskin™ as compared to a 3-lead Holter recorder. [ Time Frame: 24 hours ]
  A qualitative comparison of the relevant cardiac parameters as recorded by the Cardioskin™ to these recorded by a 3-lead Holter recorder, assessed per standard ECG analysis.
• To investigate the relation between AF episode symptoms (actively recorded by the patient) and AF episodes detected by Cardioskin™. [ Time Frame: 14 days ]
  The timing and frequency of AF symptoms as recorded by the subject and the timing, frequency and duration of AF episodes as detected by the Cardioskin™ after a 14 day recording period.
• To examine other arrhythmias as detected with the Cardioskin™ and the relation between arrhythmia symptoms (actively recorded by the patient) and arrhythmias detected by Cardioskin™. [ Time Frame: 14 days ]
  The timing and frequency of arrhythmia symptoms as recorded by the subject and the nature, timing, frequency and duration of arrhythmias as detected by the Cardioskin™ after a 14 day recording period, based on a standard ECG analysis.

Inclusion Criteria:

The subject shall only be enrolled in the clinical investigation if he/she:

• is willing and able to understand and sign informed consent, and has signed an information and inform consent;
• is male or female;
• has a documented history of AF in the 3 months prior to screening e.g. by means of an ECG report, with at least one episode ≥30 seconds;
• has a subject reported frequency of at least one AF episode in the 48 hours prior to screening, as defined by AF related complaints;
• is on stable cardiovascular medication in the 2 weeks prior to screening and no changes to the cardiovascular medication are expected for the duration of the clinical investigation;
• has body weight characteristics that are compatible with the proposed models of Cardioskin™ (the subject fits the t-shirt);
• is minimum 18 years of age when signing informed consent;
• is willing and able to comply with the instructions outlined in the User Manual of the investigational device;
• is willing and able to comply with the instructions outlined in the User Manual of the Holter recorder (;
• is willing and able to comply to the schedule of assessment of the clinical investigation.

Exclusion Criteria:

The subject shall not be enrolled in the clinical investigation if he/she:

• has an implantable loop recorder; NOTE: this exclusion criterion is not applicable to all subjects in the clinical investigation. This exclusion criterion comes into effect once 4 subjects have been enrolled with an implantable loop recorder. This number of 4 may increase, to a maximum of 10% of enrolled subjects.
• has an implanted pacemaker or defibrillator;
• is lactating, pregnant, or planning to become pregnant during the course of the clinical investigation;
• is an alcohol and/or drugs abuser, on the investigator judgement and based on the patient questioning;

• has a known allergy to one of the components of the Cardioskin™ garment, including:

  • polyamide;
  • polyester;
  • elastane;
  • silicone;
  • silver;
  • any synthetic material.
• has a known allergy to ECG stickers;
• has a lot of chest hair;
• has a sensory disorder making the patient insensitive to pain on the skin;
• has behavioural problems making the patient excessively agitated or aggressive;
• has motor or mental disorders preventing the patient from expressing pain;
• has cardiorespiratory disorders which may be aggravated by the slight compression of the thorax;
• has an open wound on the skin, in the area either covered or surrounded by Cardioskin™ textile;
• has a strong contagious risk to any material composing Cardioskin™;
• is currently participating in, or has recently exited from (within 30 days prior to screening for this clinical investigation), or plans to be enrolled (during the course of this clinical investigation) in another clinical investigation.

In addition, subjects shall be excluded on sex (male/female) if an enrolment of 60% for one of the genders has been reached. At the end of the study, maximum 60% of the enrolled subjects shall be male and maximum 60% of the subjects shall be female.